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EDITORIALTracing the Origin of Fibroblasts in Pancreatic Canceribroblasts are key players in inflammation andFcancer, secreting growth factors, ligands, and
extracellular matrix proteins that shape the microenviron-
ment.1 In pancreatic ductal adenocarcinoma (PDAC), fibro-
blasts are one of the most abundant components and
perform critical roles in therapy resistance and cancer
progression. The implementation of single-cell RNA
sequencing strategies and the development of novel in vitro
co-culture models have shown that PDAC cancer-associated
fibroblasts (CAFs) comprise distinct subtypes with different
molecular and, likely, functional features.2–8 These findings
raise the question of whether PDAC CAF subtypes have
different cells of origin. Answering this question is neces-
sary to advance our knowledge of fibroblast biology because
a particular cell of origin could at least partially determine
the molecular and functional properties of a specific CAF
subtype. Importantly, single-cell RNA sequencing analysis of
healthy pancreata has shown the presence of distinct
fibroblast populations that may represent different pre-
cursors of PDAC myofibroblastic CAFs (myCAFs) and in-
flammatory CAFs (iCAFs).3,5,7 However, whether PDAC CAF
subtypes derive from distinct cell lineages is unknown.
Indeed, until now, in vivo evidence of the cells of origin of
PDAC CAFs has been lacking.
In this issue of Cellular and Molecular Gastroenterology
and Hepatology, Garcia et al9 start to fill in this knowledge
gap by performing in vivo lineage tracing of Hoxb6, a
mesenchymal marker expressed mainly during pancreas
development, and Gli1, a target gene of the Hedgehog
signaling pathway, which is active in PDAC CAFs.10 To this
end, Garcia et al9 generated several genetically engineered
mouse models that enabled inducible labeling of cells
expressing these genes in the healthy adult pancreas and
during PDAC development. By analyzing these new mouse
models, Garcia et al9 showed that Gli1- and Hoxb6-positive
cells constitute largely nonoverlapping and spatially sepa-
rated populations in the healthy adult pancreas and differ-
entially contribute to CAFs in PDAC. In particular, Garcia
et al9 showed that only Gli1-positive fibroblasts expand
dramatically during pancreatic carcinogenesis and partially
give rise to the myCAF subtype. In addition, although most
lineage-traced Gli1-positive fibroblasts in PDAC express the
myCAF marker a-smooth muscle actin, approximately 30%
do not. However, it remains to be determined whether these
nonmyofibroblastic cells derived from Gli1-positive fibro-
blasts contribute to the inflammatory iCAF population.
Addressing this point is key because previous studies have
shown that distinct PDAC CAF subtypes are dynamic and
can interconvert in vitro and in vivo, which may indicate a
common cell of origin.6,8
The study from Garcia et al9 also challenges the common
notion that pancreatic stellate cells, which are resident cellsCellulaof the pancreas,11 are a major precursor of PDAC CAFs.
Indeed, Garcia et al9 showed that Gli1-positive fibroblasts of
the healthy pancreas, which contribute significantly to the
formation of CAFs in PDAC, do not have typical features of
pancreatic stellate cells. Although pancreatic stellate cells
co-cultured with PDAC organoids largely recapitulate the
fibroblast composition of murine and human PDAC tu-
mors,6,8 these new findings highlight the need to implement
in vitro models with other cell types that could recapitulate
different aspects of PDAC CAF heterogeneity.
The work from Garcia et al9 sparks discussion on several
additional points. As similarities in fibroblast composition
are emerging between inflammatory and malignant states,1
it will be informative to evaluate whether Gli1-positive fi-
broblasts also contribute significantly to the fibrosis of
pancreatitis models in the absence of oncogenic Kras mu-
tations. In addition, the observation that not all resident fi-
broblasts of the pancreas expand during PDAC development
raises the question of what determines the responsiveness
to cancer cell–secreted ligands of certain fibroblast pop-
ulations compared with others. It also remains to be
assessed whether pancreatic fibroblasts that do not expand
during carcinogenesis still play a role, and whether their
depletion impacts PDAC progression. Finally, because the
authors show that not all PDAC CAFs are derived from Gli1-
positive fibroblasts, it remains to be determined what other
contributors are responsible for PDAC CAF heterogeneity
in vivo. This question relates not only to resident cell pop-
ulations, but also to cell types that could be recruited from
other sites during PDAC development.
Overall, this timely study from Garcia et al9 advances our
knowledge of fibroblast heterogeneity in pancreatic cancer
and prompts new lines of investigation that could lead to
the development of novel therapeutic strategies
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